RESUMEN
Despite its widespread use, diclofenac has gastrointestinal liabilities common to nonsteroidal antiinflammatory drugs (NSAIDs) that might be reduced by concomitant administration of a gastrointestinal cytoprotectant such as nitric oxide (NO). A series of novel diclofenac esters containing a nitrosothiol (-S-NO) moiety as a NO donor functionality has been synthesized and evaluated in vivo for bioavailability, pharmacological activity, and gastric irritation. All S-NO-diclofenac derivatives acted as orally bioavailable prodrugs, producing significant levels of diclofenac in plasma within 15 min after oral administration to mice. At equimolar oral doses, S-NO-diclofenac derivatives (20a-21b) displayed rat antiinflammatory and analgesic activities comparable to those of diclofenac in the carrageenan-induced paw edema test and the mouse phenylbenzoquinone-induced writhing test, respectively. All tested S-NO-diclofenac derivatives (20a-21b) were gastric-sparing in that they elicited markedly fewer stomach lesions as compared to the stomach lesions caused by a high equimolar dose of diclofenac in the rat. Nitrosothiol esters of diclofenac comprise a novel class of NO-donating compounds having therapeutic potential as nonsteroidal antiinflammatory agents with an enhanced gastric safety profile.
Asunto(s)
Antiinflamatorios no Esteroideos/síntesis química , Diclofenaco/síntesis química , Compuestos Nitrosos/síntesis química , Profármacos/síntesis química , Animales , Antiinflamatorios no Esteroideos/química , Antiinflamatorios no Esteroideos/farmacocinética , Antiinflamatorios no Esteroideos/farmacología , Disponibilidad Biológica , Diclofenaco/química , Diclofenaco/farmacocinética , Diclofenaco/farmacología , Masculino , Ratones , Compuestos Nitrosos/química , Compuestos Nitrosos/farmacocinética , Compuestos Nitrosos/farmacología , Profármacos/química , Profármacos/farmacocinética , Profármacos/farmacología , Ratas , Ratas Sprague-Dawley , Estómago/patología , Relación Estructura-ActividadRESUMEN
We designed and evaluated a new class of molecules, nitrosylated alpha-adrenergic receptor antagonists, as potential agents for the treatment of impotence. In in vitro studies with human and rabbit corpus cavernosum strips in organ chambers, the alpha-adrenergic receptor antagonists (alpha-ARAs) moxisylyte and yohimbine and their corresponding nitrosylated compounds, SNO-moxisylyte (NMI-221) and SNO-yohimbine (NMI-187), concentration-dependently relaxed endothelin-induced contraction. The nitrosylated compounds were significantly more potent than the parent alpha-ARA. In human tissues, the specific phosphodiesterase type 5 inhibitor zaprinast potentiated the relaxing effects of the nitrosylated compounds. Only nitrosylated compounds induced accumulation of cyclic GMP in rabbit corpus cavernosum strips. Yohimbine and NMI-187 demonstrated a potent alpha2-blocking activity, with no significant differences in pA2 values (8.9 versus 8.2, respectively). Moxisylyte and NMI-221 showed moderate potency in antagonizing phenylephrine contraction, with comparable pA2 values for both molecules (6.5 versus 6.6, respectively). alpha-Adrenergic receptor-binding studies showed similar binding affinities for the alpha-ARA and their corresponding nitrosylated compounds. In vivo, intracavernosal injection of nitrosylated molecules caused greater increases in intracavernosal pressure (NMI-221 versus moxisylyte) that were more long lasting than those of moxisylyte or yohimbine. There were no significant differences between nitrosylated and non-nitrosylated compounds in the magnitude of systemic mean arterial pressure decrease after intracavernosal injection. alpha-ARA and the nitrosylated compounds showed no pain-inducing activity as evaluated with the paw-lick model in mice. In summary, nitrosylated alpha-ARA have the dual functionalities of nitric oxide donors and alpha-ARA. These drugs induced penile erection in animals, suggesting their possible therapeutic value as agents for the local pharmacological treatment of impotence.
Asunto(s)
Antagonistas Adrenérgicos alfa/síntesis química , Disfunción Eréctil/tratamiento farmacológico , Moxisilita/análogos & derivados , Compuestos Nitrosos/síntesis química , Compuestos Nitrosos/farmacología , Vasodilatadores/síntesis química , Yohimbina/análogos & derivados , Antagonistas Adrenérgicos alfa/metabolismo , Antagonistas Adrenérgicos alfa/farmacología , Animales , GMP Cíclico/metabolismo , Diseño de Fármacos , Endotelinas/farmacología , Humanos , Técnicas In Vitro , Masculino , Membranas , Ratones , Moxisilita/síntesis química , Moxisilita/metabolismo , Moxisilita/farmacología , Contracción Muscular/efectos de los fármacos , Músculo Liso Vascular/efectos de los fármacos , Pene/efectos de los fármacos , Pene/metabolismo , Pene/fisiología , Fenilefrina/farmacología , Conejos , Ratas , Ratas Sprague-Dawley , Receptores Adrenérgicos alfa 1/efectos de los fármacos , Receptores Adrenérgicos alfa 1/metabolismo , Vasodilatadores/metabolismo , Vasodilatadores/farmacología , Yohimbina/síntesis química , Yohimbina/metabolismo , Yohimbina/farmacologíaRESUMEN
Using various animal models of toxic or antigenic-induced airway inflammation, we have demonstrated that adhesion molecules play an important role in the recruitment, retention, and site-specific activation of inflammatory cells within the airways. Furthermore, we have shown that cytokines may contribute to inflammatory responses in the airways by enhancing the expression of adhesion molecules on respiratory epithelial cells.
Asunto(s)
Bronquitis/metabolismo , Moléculas de Adhesión Celular/metabolismo , Neumonía/metabolismo , Alveolos Pulmonares/metabolismo , Animales , Bronquios/metabolismo , Línea Celular , Células Cultivadas/metabolismo , Enfermedad Crónica , Modelos Animales de Enfermedad , Epitelio/metabolismo , Inmunohistoquímica , Molécula 1 de Adhesión Intercelular , Macaca fascicularis , Masculino , Ratones , Oxígeno/toxicidadRESUMEN
The distribution of intercellular adhesion molecule-1 (ICAM-1) on alveolar epithelial cells and the effects of exposure to 100% O2 on ICAM-1 expression in mouse lungs were studied by EM immunocytochemistry and immunoblot analysis. Cryoultrathin sections from mouse lungs exposed to air or 100% O2 for 84 h were labeled with a monoclonal rat anti-mouse ICAM-1 antibody. In the normal lung, abundant ICAM-1 expression was found on the alveolar surface of type I epithelial cells. Furthermore, ICAM-1 is highly concentrated on the surfaces near cell junctions. ICAM-1 was also found on the capillary surface of endothelial cells and alveolar surface of type II cells at densities considerably lower than that found on type I epithelial cells. After exposure to O2, the labeling density of ICAM-1 on the central surface of type I epithelial cells was not changed significantly. However, the gradient of ICAM-1 on the surfaces near cell junctions was nearly abolished. ICAM-1 labeling on the capillary surface of endothelial cells remained low. ICAM-1 was also markedly induced on the alveolar surface of type II epithelial cells after hyperoxic exposure. These results show that ICAM-1 is expressed primarily on type I epithelial cell surfaces near cell junctions. Exposure to hyperoxia causes a dramatic change in the distribution pattern of ICAM-1 on alveolar type I epithelial cells and induces expression of ICAM-1 on alveolar type II epithelial cells. These hyperoxia-induced changes may influence the associated neutrophil invasion/retention in the alveolar air spaces or alveolar walls.
Asunto(s)
Moléculas de Adhesión Celular/biosíntesis , Oxígeno/farmacología , Alveolos Pulmonares/metabolismo , Análisis de Varianza , Animales , Epitelio/metabolismo , Molécula 1 de Adhesión Intercelular , Masculino , Ratones , Ratones Endogámicos BALB C , Microscopía InmunoelectrónicaAsunto(s)
Antígenos/administración & dosificación , Activación de Linfocitos/inmunología , Macaca fascicularis/inmunología , Subgrupos de Linfocitos T/inmunología , Animales , Hiperreactividad Bronquial/inmunología , Líquido del Lavado Bronquioalveolar/citología , Líquido del Lavado Bronquioalveolar/inmunología , Masculino , Factores de TiempoAsunto(s)
Moléculas de Adhesión Celular/fisiología , Neumonía/patología , Animales , Anticuerpos Monoclonales/farmacología , Antígenos Helmínticos/inmunología , Ascaris suum/inmunología , Líquido del Lavado Bronquioalveolar/citología , Moléculas de Adhesión Celular/inmunología , Quimiotaxis de Leucocito , Selectina E , Peroxidasa del Eosinófilo , Eosinófilos/patología , Molécula 1 de Adhesión Intercelular/inmunología , Molécula 1 de Adhesión Intercelular/fisiología , Macaca fascicularis , Masculino , Neutrófilos/patología , Peroxidasa/metabolismo , Peroxidasas/metabolismo , Neumonía/inmunologíaRESUMEN
The direct effect of intratracheal (IT) administration of human major basic protein (MBP) on pulmonary inspiratory pressure (PIP), and the effect on agonist-induced change in PIP, were determined in anesthetized, ventilated guinea pigs. 500 micrograms MBP increased PIP from 24.1 +/- 4.3 to 49.8 +/- 7.4 cmH2O (p < 0.002, n = 10). Maximum PIP was achieved within 30 min after 500 micrograms MBP. The direct PIP response to 250 micrograms MBP was not different from vehicle. The PIP responses to intravenous (IV) acetylcholine (Ach) and 5-hydroxytryptamine (5-HT) were measured before and after administration of 250 micrograms MBP (n = 12). MBP caused a modest, but significant potentiation of the increase in PIP induced by 1, 3 and 10 micrograms/kg Ach (24, 32 and 28%, respectively, p < 0.02) and to 1 microgram/kg 5-HT (43% p < 0.02). We conclude that MBP at a dose that does not directly affect inspiratory pressure is capable of augmenting the PIP response to IV Ach and 5-HT in vivo.
Asunto(s)
Acetilcolina/farmacología , Proteínas Sanguíneas/farmacología , Broncoconstricción/efectos de los fármacos , Pulmón/efectos de los fármacos , Ribonucleasas , Serotonina/farmacología , Animales , Proteínas en los Gránulos del Eosinófilo , Cobayas , Humanos , Masculino , Tráquea/efectos de los fármacosRESUMEN
Cell surface adhesive glycoproteins are principal regulators of nearly all aspects of immune/inflammatory responses. Using monoclonal antibodies to individual adhesion molecules, the expression and contribution of specific molecules in the pathogenesis of allergen-induced airway hyperresponsiveness in monkeys has been deciphered. Results confirm the importance of cell adhesion and demonstrate that antagonism of a single adhesion molecule may provide a novel therapeutic approach.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Asma/terapia , Moléculas de Adhesión Celular/inmunología , Animales , Modelos Animales de Enfermedad , Humanos , Inflamación/terapia , Enfermedades de los Monos/terapia , Primates , Terminología como AsuntoRESUMEN
Cell surface adhesive glycoproteins are principal regulators of nearly all aspects of immune/inflammatory responses. Using monoclonal antibodies to individual adhesion molecules, the expression and contribution of specific molecules in the pathogenesis of allergen-induced airway hyperresponsiveness in monkeys has been studied. Results confirm the importance of cell adhesion and demonstrate that antagonism of a single adhesion molecule may provide a novel therapeutic approach.
Asunto(s)
Moléculas de Adhesión Celular/fisiología , Inflamación/inmunología , Animales , Endotelio/inmunología , Epitelio/inmunología , Humanos , Leucocitos/fisiología , Unión ProteicaAsunto(s)
Asma/fisiopatología , Hiperreactividad Bronquial/fisiopatología , Moléculas de Adhesión Celular/inmunología , Animales , Asma/inmunología , Asma/terapia , Hiperreactividad Bronquial/inmunología , Hiperreactividad Bronquial/terapia , Moléculas de Adhesión Celular/clasificación , Modelos Animales de Enfermedad , Humanos , Inmunoglobulina E/inmunología , Pulmón/fisiología , Macaca fascicularis , Masculino , Mastocitos/inmunologíaRESUMEN
We have examined the proinflammatory cell influx as well as the levels of eosinophil and neutrophil-derived granule proteins in BAL fluid obtained from monkeys undergoing acute and late-phase (dual) or single acute bronchoconstriction following antigen inhalation. Prior to antigen inhalation, there was a significantly higher number (and percentage) of eosinophils in BAL fluid from dual responder monkeys as compared with single responders. The late-phase response (LPR) (6 to 8 h postantigen) was associated with a decrease in the number of BAL eosinophils and an increase in the levels of BAL fluid EPO that returned to baseline levels by 24 h postantigen inhalation. In contrast, the number of BAL neutrophils prior to antigen inhalation were low. Concurrent with the LPR, the number of BAL neutrophils and the concentration of EPO in BAL fluid were significantly increased above that occurring in single responders. Chronic treatment (7 days) with dexamethasone significantly reduced the number of BAL eosinophils and the BAL levels of EPO prior to antigen inhalation in dual responder (LPR) monkeys and significantly blocked the dual response and both the associated neutrophil influx into the airways and an increase in BAL fluid EPO during the LPR. We conclude that, in this primate model, eosinophil activation and a large influx of neutrophils into the airways is associated with the occurrence of the antigen-induced late-phase airway obstructive response.
Asunto(s)
Reacción de Fase Aguda/inmunología , Antígenos/efectos adversos , Asma/fisiopatología , Hiperreactividad Bronquial/complicaciones , Hipersensibilidad Tardía/inmunología , Reacción de Fase Aguda/complicaciones , Reacción de Fase Aguda/diagnóstico , Administración por Inhalación , Resistencia de las Vías Respiratorias , Animales , Antígenos/administración & dosificación , Hiperreactividad Bronquial/inducido químicamente , Hiperreactividad Bronquial/tratamiento farmacológico , Líquido del Lavado Bronquioalveolar/química , Dexametasona/administración & dosificación , Dexametasona/uso terapéutico , Modelos Animales de Enfermedad , Eosinófilos/química , Estudios de Evaluación como Asunto , Hipersensibilidad Tardía/complicaciones , Hipersensibilidad Tardía/diagnóstico , Macaca fascicularis , Masculino , Neutrófilos/químicaRESUMEN
We have examined the role of intercellular adhesion molecule-1 (ICAM-1) in chronic airway inflammation and airway hyperresponsiveness in a primate model of asthma. Airway cellular composition was assessed by bronchoalveolar lavage (BAL) and airway responsiveness was measured as the bronchoconstrictor response to inhaled methacholine. In animals with chronic airway inflammation (increased BAL eosinophils) and sustained airway hyperresponsiveness, a 7 day dosing scheme with a murine anti-human ICAM-1 monoclonal antibody (R6.5, 2 mg/kg/day; i.v.) did not reduce the existing airway inflammation or airway hyperresponsiveness. In contrast, a similar dosing scheme with dexamethasone (0.2 mg/kg/day, i.m.) was found to significantly reduce both the airway eosinophilia and hyperresponsiveness. However, one week after cessation of dexamethasone treatment, the airway inflammation and hyperresponsiveness returned to pre-treatment levels. In further experiments where animals were first treated with dexamethasone (7 days) followed by a 7 day treatment with R6.5, the reoccurrence of airway inflammation and subsequent increase in airway responsiveness was prevented. We conclude that the efficacy of ICAM-1 is primarily associated with inhibition of the influx of inflammatory cells into the airways and subsequent reduction in airway responsiveness. These data suggest that in lungs with pre-existing inflammation the modulation of ICAM-1 following treatment with glucocorticoids may be a novel and more selective long-term treatment for control of the chronic airway inflammation and hyperresponsiveness associated with bronchial asthma.
Asunto(s)
Asma/etiología , Moléculas de Adhesión Celular/fisiología , Resistencia de las Vías Respiratorias/fisiología , Animales , Anticuerpos Monoclonales/administración & dosificación , Asma/fisiopatología , Asma/terapia , Líquido del Lavado Bronquioalveolar/patología , Broncoconstricción/fisiología , Moléculas de Adhesión Celular/inmunología , Modelos Animales de Enfermedad , Eosinófilos/patología , Glucocorticoides/administración & dosificación , Inflamación/etiología , Inflamación/terapia , Molécula 1 de Adhesión Intercelular , Macaca fascicularis , MasculinoAsunto(s)
Moléculas de Adhesión Celular/fisiología , Enfermedades Pulmonares/fisiopatología , Animales , Moléculas de Adhesión Celular/metabolismo , Selectina E , Endotelio Vascular/metabolismo , Epitelio/metabolismo , Haplorrinos , Humanos , Inflamación/fisiopatología , Molécula 1 de Adhesión Intercelular , Pulmón/citología , Pulmón/efectos de los fármacos , Enfermedades Pulmonares/etiología , Ratones , Oxígeno/toxicidad , Hipersensibilidad Respiratoria/fisiopatologíaRESUMEN
Previous studies from our laboratory have demonstrated a temporal relationship between eosinophil influx into the airways and the onset of airway hyperresponsiveness to inhaled methacholine. The purpose of the present study was to extend this observation by evaluating changes in airway cellular composition and measuring the levels of granulocyte-derived mediators recovered in BAL fluid during the onset and recovery from antigen-induced airway hyperresponsiveness. Airway cellular composition, airway responsiveness to inhaled methacholine and the levels of BAL fluid EPO and MPO were monitored over a 32 day study in eight adult male Ascaris suum sensitive cynomolgus monkeys. Repeated Ascaris suum inhalation (nine challenges during days 0-21) resulted in a selective, sustained airway eosinophilia that was temporally related with the onset and maintenance of airway hyperresponsiveness (r = 0.67, P less than 0.001). The level of BAL eosinophil-derived EPO was increased and remained elevated concurrent with the increase in airway eosinophils and airway responsiveness. During the recovery phase (days 22-32) the actual number of eosinophils remained elevated, while BAL EPO levels were significantly decreased. The recovery phase was also associated with a transient increase in the number of BAL neutrophils and MPO concentration. We conclude that the number and state of activation of airway eosinophils directly correlate with the onset and maintenance of airway hyperresponsiveness. Recovery from airway hyperresponsiveness is associated with a decrease in eosinophil activation and a transient increase in the number of activated neutrophils.
Asunto(s)
Hipersensibilidad Respiratoria/fisiopatología , Resistencia de las Vías Respiratorias , Animales , Ascaris/inmunología , Líquido del Lavado Bronquioalveolar/patología , Citotoxicidad Inmunológica , Granulocitos/metabolismo , Inflamación/patología , Macaca fascicularis , Masculino , Cloruro de Metacolina , Proteínas/metabolismo , Hipersensibilidad Respiratoria/metabolismo , Hipersensibilidad Respiratoria/patologíaRESUMEN
Platelet-activating factor (PAF) is a potent pro-inflammatory mediator that may play a role in the pathogenesis of airway hyper-responsiveness and asthma. In man, a single inhalation of PAF induces a small but prolonged increase in airway responsiveness in some individuals. The purpose of this study was to determine the effects of single and multiple inhalations of PAF on airway cell composition and responsiveness in monkeys. Anaesthetized and intubated adult male cynomolgus monkeys were studied. Airway cell composition was measured by bronchoalveolar lavage (BAL). Airway responsiveness was measured by determining the concentration (PC100) of inhaled methacholine that caused a 100% increase in respiratory system resistance (Rrs). Airway cell composition (BAL) and responsiveness (PC100) were determined 1 day before and 20 hr after a single inhalation of PAF (approximately 200 micrograms) or 3 days before (Day 0) and 3 days after (Day 10) 3-alternate-day (Days 3, 5 and 7) inhalations of PAF (each approximately 600 micrograms). The single inhalation of PAF (n = 8) caused an acute increase in Rrs (147 +/- 69%), an increase in BAL granulocytes, and a decrease in PC100 in four of eight animals that was moderate (greater than eight fold) in only one animal. The mean +/- s.e. change in log PC100 was -0.29 +/- 0.18. The multiple inhalations of PAF (n = 8) caused acute increases in Rrs (143 +/- 38%, 175 +/- 44% and 156 +/- 39%, respectively), an increase in BAL granulocytes, and a decrease in PC100 in four of eight animals that was moderate in two animals. The mean +/- s.e. change in log PC100 was -0.43 +/- 0.22.
Asunto(s)
Factor de Activación Plaquetaria/administración & dosificación , Sistema Respiratorio/efectos de los fármacos , Administración por Inhalación , Animales , Asma/etiología , Líquido del Lavado Bronquioalveolar/citología , Broncoconstricción/efectos de los fármacos , Eosinófilos/citología , Macaca fascicularis , Masculino , Neutrófilos/citología , Fenómenos Fisiológicos Respiratorios , Sistema Respiratorio/citologíaRESUMEN
The development of selective PAF receptor antagonists may provide a novel approach to the treatment of human bronchial asthma. In preclinical animal models of human asthma, PAF receptor antagonists have been found to be efficacious in blocking antigen-induced changes in lung function. However, the majority of these models involve acute inflammatory events and transient changes in lung function and, therefore, their relevance to human asthma is questionable. In a recent study with a primate model of chronic airway inflammation and hyperresponsiveness, we have shown that treatment with a PAF receptor antagonist had no effect on reducing chronic inflammation and hyperresponsiveness. Similarly, recent studies in human asthmatics with PAF receptor antagonists have failed to show efficacy in blocking allergen-induced airway responses or to have any steroid sparing effects in patients with ongoing asthma. Thus, it seems that PAF may not be a key mediator which can be blocked and thereby provide therapy for bronchial asthma.
RESUMEN
We have examined the effects of a PAF receptor antagonist, WEB 2170, on several indices of acute and chronic airway inflammation and associated changes in lung function in a primate model of allergic asthma. A single oral administration WEB 2170 provided dose related inhibition of the release of leukotriene C(4) (LTC(4)) and prostaglandin D(2) (PGD(2)) recovered and quantified in bronchoalveolar lavage (BAL) fluid obtained during the acute phase response to inhaled antigen. In addition, oral WEB 2170 treatment in dual responder primates blocked the acute influx of neutrophils into the airways as well as the associated late-phase airway obstruction occurring 6 h after antigen inhalation. In contrast, a multiple dosing regime with WEB 2170 (once a day for 7 consecutive days) failed to reduce the chronic airway inflammation (eosinophilic) and associated airway hyperresponsiveness to inhaled methacholine that is characteristic of dual responder monkeys. Thus, we conclude that the generation of PAF following antigen inhalation contributes to the development of lipid mediators, acute airway inflammation and associated late-phase airway obstruction in dual responder primates; however, PAF does not play a significant role in the maintenance of chronic airway inflammation and associated airway hyperresponsiveness in this primate model.
RESUMEN
In immature or injured lungs, impaired alveolar gas exchange forces the use of elevated levels of inhaled oxygen to maintain life. But, at high concentrations oxygen induces lung injury, edema, and bronchopulmonary dysplasia, probably by stimulating the generation of reactive oxygen radicals and subsequent neutrophil infiltration. In addition to regulating neutrophil diapedesis, intercellular adhesion molecule-1 (ICAM-1) expression is marked on inflamed alveolar epithelium, suggesting a role for ICAM-1 in oxygen-induced, neutrophil-mediated parenchymal damage. To test this, we evaluated the rat anti-mouse ICAM-1 monoclonal antibody YN1/1.7 in 2 protocols of oxygen-induced toxicity in adult, male Balb-c mice: greater than or equal to 95% O2 for 84 hr and greater than or equal to 95% O2 for 60 hr followed by 48 hr at 21% (ambient) O2. YN1/1.7 treatment partially attenuated the neutrophil infiltration, lung damage (lavage lactate dehydrogenase [LDH] activity) and dysfunction (reductions in respiratory system compliance [Crs] and diffusion capacity of the lungs for carbon monoxide [DLCO] in the 84 hr exposure protocol. In the milder 60 hr exposure protocol, YN1/1.7 completely blocked the oxygen-induced lung dysfunction (reductions in Crs and DLco). These results confirm the contribution of leukocytes in the pathogenesis of pulmonary oxygen toxicity and indicate that antagonism of ICAM-1 may provide a therapeutic approach to reducing hyperoxic lung injury and dysfunction.
Asunto(s)
Anticuerpos Monoclonales/administración & dosificación , Moléculas de Adhesión Celular/fisiología , Enfermedades Pulmonares/terapia , Terapia por Inhalación de Oxígeno/efectos adversos , Oxígeno/efectos adversos , Animales , Evaluación Preclínica de Medicamentos , Molécula 1 de Adhesión Intercelular , Enfermedades Pulmonares/inducido químicamente , Masculino , Ratones , Ratones Endogámicos BALB C , Neutrófilos/efectos de los fármacosRESUMEN
This study examines the role of endothelial leukocyte adhesion molecule-1 (ELAM-1) in the development of the acute airway inflammation (cell influx) and late-phase airway obstruction in a primate model of extrinsic asthma. In animals sensitive to antigen, a single inhalation exposure induced the rapid expression of ELAM-1 (6 h) exclusively on vascular endothelium that correlated with the influx of neutrophils into the lungs and the onset of late-phase airway obstruction. In contrast, basal levels of ICAM-1 was constitutively expressed on vascular endothelium and airway epithelium before antigen challenge. After the single antigen exposure, changes in ICAM-1 expression did not correlate with neutrophil influx or the change in airway caliber. This was confirmed by showing that pretreatment with a monoclonal antibody to ICAM-1 did not inhibit the acute influx of neutrophils associated with late-phase airway obstruction, whereas a monoclonal antibody to ELAM-1 blocked both the influx of neutrophils and the late-phase airway obstruction. This study demonstrates a functional role for ELAM-1 in the development of acute airway inflammation in vivo. We conclude that, in primates, the late-phase response is the result of an ELAM-1 dependent influx of neutrophils. Therefore, the regulation of ELAM-1 expression may provide a novel approach to controlling the acute inflammatory response, and thereby, affecting airway function associated with inflammatory disorders, including asthma.